echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Ann Hematol: ixazomib oral treatment is expected to be a good alternative treatment option for NDMM patients

    Ann Hematol: ixazomib oral treatment is expected to be a good alternative treatment option for NDMM patients

    • Last Update: 2021-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The induction therapy of oral proteasome inhibitor ixazomib has shown good efficacy and safety in clinical trials, but its experience in real life is still limited


    COVID-19 diagnosis

    The treatment regimen based on ixazomib included 44.


     

    Ten patients received maintenance treatment with ixazomib


    In summary, these results support ixazomib as a first-line therapy in routine practice, and the toxicity of ixazomib can be tolerated.


     

    Original source:

     

    Jing Li ,Li Bao , et al.


    Li jing Li Bao Ixazomib-based Frontline Therapy in patients with newly diagnosed Multiple myeloma in Real-Life Practice Showed the Comparable efficacy and Safety Profile with Those Reported in Clinical Trial: A Multi-Center Study

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.